Literature DB >> 19969591

Catatonia and its treatment.

Patricia I Rosebush1, Michael F Mazurek.   

Abstract

Psychiatric diagnoses are currently categorized on a syndromic basis. The syndrome of catatonia, however, remains in a diagnostic limbo, acknowledged predominantly as a subtype of schizophrenia. Yet, catatonia is present in about 10% of acutely ill psychiatry patients, only a minority of whom have schizophrenia. Among those with comorbid affective disorders, who comprise the largest subgroup of catatonic patients, the catatonic signs typically resolve dramatically and completely with benzodiazepine therapy. Those with schizophrenia respond less reliably, suggesting that the underlying processes causing the catatonia may be different in this group. The majority of patients with catatonia have concurrent psychosis. Failure to treat the catatonia before institution of antipsychotic medication may increase the risk of inducing neuroleptic malignant syndrome. At this point of time, the pathobiology of catatonia is unknown; the major reason for considering catatonia as a separate diagnostic entity would be to increase recognition of this eminently treatable neuropsychiatric syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969591      PMCID: PMC2833127          DOI: 10.1093/schbul/sbp141

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  21 in total

1.  Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study.

Authors:  G S Ungvari; H F Chiu; L Y Chow; B S Lau; W K Tang
Journal:  Psychopharmacology (Berl)       Date:  1999-03       Impact factor: 4.530

2.  Lorazepam as an adjunct in the treatment of catatonic states: an open clinical trial.

Authors:  R Yassa; H Iskandar; M Lalinec; L Cleto
Journal:  J Clin Psychopharmacol       Date:  1990-02       Impact factor: 3.153

3.  Serum iron and neuroleptic malignant syndrome.

Authors:  P I Rosebush; M F Mazurek
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

4.  Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam.

Authors:  P I Rosebush; A M Hildebrand; B G Furlong; M F Mazurek
Journal:  J Clin Psychiatry       Date:  1990-09       Impact factor: 4.384

5.  Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers.

Authors:  G S Gaind; P I Rosebush; M F Mazurek
Journal:  J Clin Psychiatry       Date:  1994-01       Impact factor: 4.384

6.  Catatonia after benzodiazepine withdrawal.

Authors:  P I Rosebush; M F Mazurek
Journal:  J Clin Psychopharmacol       Date:  1996-08       Impact factor: 3.153

7.  Benzodiazepines in the treatment of catatonic syndrome.

Authors:  G S Ungvari; C M Leung; M K Wong; J Lau
Journal:  Acta Psychiatr Scand       Date:  1994-04       Impact factor: 6.392

8.  Catatonia. I. Rating scale and standardized examination.

Authors:  G Bush; M Fink; G Petrides; F Dowling; A Francis
Journal:  Acta Psychiatr Scand       Date:  1996-02       Impact factor: 6.392

9.  Serum iron in catatonia and neuroleptic malignant syndrome.

Authors:  J W Lee
Journal:  Biol Psychiatry       Date:  1998-09-15       Impact factor: 13.382

Review 10.  Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues.

Authors:  P I Rosebush; G M MacQueen; J T Clarke; J W Callahan; P M Strasberg; M F Mazurek
Journal:  J Clin Psychiatry       Date:  1995-08       Impact factor: 4.384

View more
  49 in total

Review 1.  Revisiting the diagnosis of schizophrenia: where have we been and where are we going?

Authors:  William R Keller; Bernard A Fischer; William T Carpenter
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

2.  Treatment use in a prospective naturalistic cohort of children and adolescents with catatonia.

Authors:  Marie Raffin; Laetitia Zugaj-Bensaou; Nicolas Bodeau; Vanessa Milhiet; Claudine Laurent; David Cohen; Angèle Consoli
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-08-27       Impact factor: 4.785

3.  Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses.

Authors:  Hadar Zaman; Roger Carl Gibson; Geoffrey Walcott
Journal:  Cochrane Database Syst Rev       Date:  2019-08-05

4.  Catatonia in the DSM--shall we move or not?

Authors:  Stephan Heckers; Rajiv Tandon; Juan Bustillo
Journal:  Schizophr Bull       Date:  2009-11-23       Impact factor: 9.306

5.  Catatonia in psychotic patients: clinical features and treatment response.

Authors:  Mary L England; Dost Ongür; Glenn T Konopaske; Rakesh Karmacharya
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

6.  Catatonia in resource-limited settings: a case series and treatment protocol.

Authors:  Stephanie L Smith; David J Grelotti; Reginald Fils-Aime; Eugenie Uwimana; Jean-Sauveur Ndikubwimana; Tatiana Therosme; Jennifer Severe; Dominique Dushimiyimana; Clemence Uwamariya; Robert Bienvenu; Yoldie Alcindor; Eddy Eustache; Giuseppe J Raviola; Gregory L Fricchione
Journal:  Gen Hosp Psychiatry       Date:  2014-10-30       Impact factor: 3.238

7.  Still trying to solve the catatonic dilemma--A comment on the Letter to the Editor by Loeb et al. (Psychopharmacology, 2015).

Authors:  Fabian U Lang; Silke Lang; Thomas Becker; Markus Jäger
Journal:  Psychopharmacology (Berl)       Date:  2015-06-09       Impact factor: 4.530

8.  Clozapine for the management of persistent catatonia.

Authors:  Karim Tabbane; Soumeyya Halayem; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2016-10       Impact factor: 6.186

Review 9.  Clinical Predictors of Response to Clozapine in Patients with Treatment Resistant Schizophrenia.

Authors:  Rajkumar A P; Chitra C; Bhuvaneshwari S; Poonkuzhali B; Kuruvilla A; Jacob K S
Journal:  Psychopharmacol Bull       Date:  2011-09-15

10.  Psychosis and catatonia in fragile X: Case report and literature review.

Authors:  Tri Indah Winarni; Andrea Schneider; Neera Ghaziuddin; Andreea Seritan; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.